Get the Stockscreener App
14.59
9.99%
-1.62
Atento S.A. Ordinary Shares stock is traded at $14.59, with a volume of 262.32K.
It is down -9.99% in the last 24 hours and down -35.98% over the past month.
Atento S.A., together with its subsidiaries, provides customer relationship management and business process outsourcing services and solutions in Brazil, the Americas, Europe, the Middle East, and Africa. It offers a range of front and back-end services, including sales, customer care, collections, back office, applications-processing, credit-management, and technical support services. The company serves clients primarily in the telecommunications and financial services sectors; and in multi-sectors, including consumer goods, retail, public administration, healthcare, travel, and transportation and logistics, as well as technology and media. It provides its services and solutions through digital channels, which include SMS, email, chats, social media and apps, and others, as well as through voice and in-person. The company was formerly known as Atento Floatco S.A. Atento S.A. was founded in 1999 and is based in Findel, Luxembourg.
See More
Previous Close:
$16.21
Open:
$16.21
24h Volume:
262.32K
Relative Volume:
0.53
Market Cap:
$666.05M
Revenue:
$1.42B
Net Income/Loss:
$-140.69M
P/E Ratio:
-1.4982
EPS:
-9.7385
Net Cash Flow:
$10.77M
1W Performance:
-18.92%
1M Performance:
-35.98%
6M Performance:
+2,994%
1Y Performance:
+2,994%
1-Day Range:
$14.44
$16.30
1-Week Range:
$14.44
$18.38
52-Week Range:
$0.4248
$28.00
Atento S.A. Ordinary Shares Stock (ATTO) Company Profile
Name
Atento S.A. Ordinary Shares
Sector
Industry
Phone
-
Address
4, Rue Lou Hemmer, Findel
Compare ATTO vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATTO
Atento S.A. Ordinary Shares
|
14.59 | 666.05M | 1.42B | -140.69M | 10.77M | -9.7385 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atento S.A. Ordinary Shares Stock (ATTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-26 | Initiated | Citigroup | Buy |
| Aug-31-26 | Initiated | Leerink Partners | Outperform |
| Aug-31-26 | Initiated | Morgan Stanley | Overweight |
| Aug-31-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Upgrade | Goldman | Sell → Neutral |
| Apr-30-20 | Downgrade | Goldman | Neutral → Sell |
| Jun-05-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-07-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Aug-21-17 | Reiterated | Barrington Research | Outperform |
| Apr-24-17 | Initiated | Barrington Research | Outperform |
| May-11-16 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-09-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-11-14 | Initiated | Robert W. Baird | Outperform |
View All
Atento S.A. Ordinary Shares Stock (ATTO) Latest News
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire
Goldman units trade Attovia Therapeutics (ATTO) shares, add swaps - Stock Titan
Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock - Stock Titan
Atento S.A. (OTC: ATTOF) Stock Price, News & Analysis - kalkine.ca
Goldman Sachs entities (NYSE: ATTO) report Attovia stock conversions and market-making trades - Stock Titan
Frazier Life Sciences XI Discloses Investment at Attovia Therapeutics with 13.5% Stake - tradingview.com
Frazier Life Sciences funds (ATTO) detail Attovia stakes and IPO purchases - Stock Titan
Attovia Therapeutics (ATTO) insider reports initial stock and option holdings - Stock Titan
Attovia Therapeutics (ATTO) major holder converts 18.2M preferred into common - Stock Titan
Attovia Therapeutics (ATTO) director discloses 72,792-share option grant and vesting terms - Stock Titan
ATTO SEC FilingsAttovia Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Attovia Therapeutics (ATTO) CMO Hubert Chen discloses stock and option positions - Stock Titan
Attovia Therapeutics (Nasdaq:ATTO)Stock Analysis - Simply Wall Street
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - finance.yahoo.com
Attovia Therapeutics Prices Upsized $289 Million Initial Public Offering - Quiver Quantitative
Attovia Therapeutics prices IPO at $17 per share on Nasdaq By Investing.com - Investing.com Nigeria
Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com India
Attovia Therapeutics prices upsized IPO at $17 per share - Investing.com
Attovia's 17M-share IPO is expected to begin Nasdaq Global Market trading Aug. 5 - Stock Titan
Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com
Redmile Group (ATTO) reports Series B preferred stake convertible into 782,854 shares - Stock Titan
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive
Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs - Seeking Alpha
Attovia Therapeutics Begins IPO Effort On Promising Early Trials (ATTO) - Seeking Alpha
Attovia Therapeutics files for IPO on Nasdaq - Investing.com
Attovia Therapeutics files for IPO on Nasdaq By Investing.com - Investing.com Nigeria
Atento SA stock (LU0992182062): Why Google Discover changes matter more now - AD HOC NEWS
Atento SA stock (LU0992182062): Why mobile-first delivery now matters more for customer experience i - AD HOC NEWS
Atento SA Stock (ISIN: LU0992182062) Faces Uncertainty Amid Sparse Market Activity - AD HOC NEWS
Attovia Therapeutics, Inc. (ATTO) Stock Price, News, Quote & History - Yahoo Finance
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Atento S.A. Ordinary Shares Stock (ATTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atento S.A. Ordinary Shares Stock (ATTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WALSH COLIN | Director |
Aug 06 '26 |
Buy |
17.00 |
500,000 |
8,500,000 |
3,020,632 |
| venBio Global Strategic Fund I | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
382,352 |
6,499,984 |
4,181,367 |
| Redmile Group, LLC | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
400,000 |
6,800,000 |
1,182,854 |
| Redmile Group, LLC | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
200,000 |
3,400,000 |
982,854 |
| Frazier Life Sciences XI, L.P. | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
588,235 |
9,999,995 |
6,154,213 |
| GOLDMAN SACHS GROUP INC | Former 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
500,000 |
8,500,000 |
3,020,632 |
| Sanofi | 10% Owner |
Aug 06 '26 |
Buy |
17.00 |
300,000 |
5,100,000 |
1,082,855 |
| WALSH COLIN | Director |
Aug 05 '26 |
Buy |
21.00 |
85,000 |
1,785,000 |
85,000 |
| WALSH COLIN | Director |
Aug 05 '26 |
Sale |
21.28 |
105,807 |
2,251,658 |
0 |
| GOLDMAN SACHS GROUP INC | Former 10% Owner |
Aug 05 '26 |
Buy |
21.00 |
85,000 |
1,785,000 |
85,000 |
0.61%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):